Japan's Price Cuts Slated For April Bring Old, New Blues For Industry
Xolair, Lixiana, Keytruda Hard Hit
Next month’s regular reimbursement price cut in Japan includes some large reductions for big-selling drugs, while one new rule has been applied for the first time.
You may also be interested in...
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.
The European research-based pharma industry in Japan continues to call for a pricing system that better encourages innovation and for inclusive discussions on reforms that address health system challenges and focus on patients.
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.